Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli.

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

As part of the CURE® Educated Patient® Summit, one expert reviewed the landscape of bispecific antibodies, such as Tecvayli, for multiple myeloma.

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

When I told my friends and family I have multiple myeloma, some of them didn't know what to do.

New drug combinations and sequences are being investigated and may improve outcomes for patients with newly diagnosed myeloma, an expert explained at the Educated Patient® Multiple Myeloma Summit.